Mobileye Global (NASDAQ:MBLY – Free Report) had its price objective decreased by Canaccord Genuity Group from $27.00 to $25.00 in a report published on Friday morning, Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.
Several other research firms also recently weighed in on MBLY. Morgan Stanley upgraded shares of Mobileye Global from an “underweight” rating to an “equal weight” rating and dropped their target price for the company from $25.00 to $18.00 in a report on Friday, August 2nd. Fox Advisors downgraded shares of Mobileye Global from an “overweight” rating to an “equal weight” rating in a report on Thursday, August 1st. Barclays dropped their target price on shares of Mobileye Global from $27.00 to $19.00 and set an “overweight” rating for the company in a report on Tuesday, October 15th. Hsbc Global Res upgraded shares of Mobileye Global to a “strong-buy” rating in a report on Monday, July 15th. Finally, HSBC started coverage on shares of Mobileye Global in a report on Monday, July 15th. They issued a “buy” rating and a $33.00 target price for the company. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $23.20.
View Our Latest Stock Report on MBLY
Mobileye Global Stock Performance
Institutional Investors Weigh In On Mobileye Global
Several institutional investors have recently modified their holdings of the company. Advisors Asset Management Inc. lifted its position in shares of Mobileye Global by 9.9% during the 1st quarter. Advisors Asset Management Inc. now owns 8,608 shares of the company’s stock worth $277,000 after purchasing an additional 774 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its stake in Mobileye Global by 24.7% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 6,299 shares of the company’s stock worth $203,000 after acquiring an additional 1,248 shares in the last quarter. Guinness Atkinson Asset Management Inc raised its stake in Mobileye Global by 16.9% during the 3rd quarter. Guinness Atkinson Asset Management Inc now owns 8,700 shares of the company’s stock worth $119,000 after acquiring an additional 1,257 shares in the last quarter. Levin Capital Strategies L.P. raised its stake in Mobileye Global by 11.1% during the 2nd quarter. Levin Capital Strategies L.P. now owns 14,441 shares of the company’s stock worth $406,000 after acquiring an additional 1,441 shares in the last quarter. Finally, Lipe & Dalton raised its stake in Mobileye Global by 53.6% during the 1st quarter. Lipe & Dalton now owns 4,300 shares of the company’s stock worth $138,000 after acquiring an additional 1,500 shares in the last quarter. 13.25% of the stock is owned by hedge funds and other institutional investors.
Mobileye Global Company Profile
Mobileye Global Inc develops and deploys advanced driver assistance systems (ADAS) and autonomous driving technologies and solutions worldwide. The company operates through Mobileye and Other segments. It offers Driver Assist comprising ADAS and autonomous vehicle solutions that covers safety features, such as real-time detection of road users, geometry, semantics, and markings to provide safety alerts and emergency interventions; Cloud-Enhanced Driver Assist, a solution for drivers with interpretations of a scene in real-time; Mobileye SuperVision Lite, a navigation and assisted driving solution; and Mobileye SuperVision, an operational point-to-point assisted driving navigation solution on various road types and includes cloud-based enhancements, such as road experience management.
Read More
- Five stocks we like better than Mobileye Global
- What is a Dividend King?
- Intel: Is Now the Time to Be Brave?
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Why Are Stock Sectors Important to Successful Investing?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Mobileye Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mobileye Global and related companies with MarketBeat.com's FREE daily email newsletter.